Navigation Links
Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs

BRIDGEWATER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S., an affiliate of sanofi-aventis, one of the world's leading pharmaceutical companies, announced today that starting January 1, 2009, it has increased access to its non-oncology Patient Assistance Programs (PAP)s to include eligible uninsured patients with incomes up to 250% of the Federal Poverty Level.

These PAPs assist patients with limited financial resources in gaining access to needed sanofi-aventis U.S. prescription medicines by focusing on individual patients and acting as a resource for those patients and their advocates. Uninsured individuals with income levels of up to $26,000 and uninsured families of four with combined income of up to $53,000 may be eligible to receive sanofi-aventis U.S. prescription drugs at no charge through the expanded U.S. Traditional PAP.*

"Sanofi-aventis U.S. remains committed to making our prescription medicines available to uninsured and low income patients through our PAPs," stated Greg Irace, President and CEO of sanofi-aventis U.S. "We have taken several steps to help patients with the greatest financial need access these medications."

The sanofi-aventis U.S. Patient Assistance Programs include medicines for many different disease states, including: Diabetes, Rheumatoid Arthritis, Urology, Dermatology, Blood Clotting (Deep Vein Thrombosis, Pulmonary Embolism), and Allergies. For more information, please contact the sanofi-aventis U.S. Traditional PAP at 1-800-221-4025.

PACT+(R) (Providing Access to Cancer Therapy), is Sanofi-aventis U.S.'s PAP for Cancer medications. PACT+ provides access to our oncology brands for eligible low income patients with an income of no greater than 500 percent of the Federal Poverty Level. PACT+ also provides reimbursement support services plus offers help in identifying a variety of alternative services and resources to support the specific needs of cancer patients. For more information on PACT+, please call 1-800-996-6626.

In addition, sanofi-aventis U.S. is a proud participant in The Partnership for Prescription Assistance which brings together America's pharmaceutical companies, doctors, other health care providers, patient advocacy organizations and community groups to help qualifying patients who lack prescription coverage get the medicines they need through the public or private program that's right for them. Call 1-888-477-2669 or visit

*Federal Poverty Limits change annually and are issued by the US Department of Health and Human Services.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, visit: or

Contact: Marc Greene, sanofi-aventis, 212-551-4780

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
3. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
4. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
5. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
6. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
7. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
8. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
9. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
10. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
11. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: